Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases

• Published in: BMC psychiatry Vol. 10; no. 1; p. 43
• Main Authors: Detke, Holland C, McDonnell, David P, Brunner, Elizabeth, Zhao, Fangyi, Sorsaburu, Sebastian, Stefaniak, Victoria J, Corya, Sara A
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.06.2010; BioMed Central; BMC
• Subjects: Antipsychotic Agents - administration & dosage; Antipsychotic Agents - adverse effects; Antipsychotic Agents - therapeutic use; Benzodiazepines - administration & dosage; Benzodiazepines - adverse effects; Benzodiazepines - therapeutic use; Care and treatment; Clinical Trials as Topic - statistics & numerical data; Cognition Disorders; Complications and side effects; Delayed-Action Preparations; Delirium; Delirium - chemically induced; Delirium - epidemiology; Development and progression; Dosage and administration; Drug Administration Schedule; Drug Overdose - epidemiology; Drug Overdose - etiology; Drug-Related Side Effects and Adverse Reactions - diagnosis; Drug-Related Side Effects and Adverse Reactions - metabolism; Humans; Incidence; Injections, Intramuscular; Olanzapine; Research article; Risk Factors; Schizophrenia; Schizophrenia - diagnosis; Schizophrenia - drug therapy; Sleep - drug effects; Syndrome; Treatment Outcome; United States

An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified i...